Imedex E-learning (audio)

Autor: Vários
Narrador: Vários
Editora: Podcast
Duração: 188:39:35

Mais informações

Seguir

Ouvir

Escolher este livro

Ouvir

Sinopse

New and exciting data presented each day during the conference and address the potential impact on current clinical practice.

Mostrar mais

Episódios

Chemotherapy vs Novel Agents in Young CLL Patients: Is There Still a Role for Chemotherapy? - Neil E. Kay, MD

31/12/2019 Duração: 16min

First- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy

Ouvir
Panel Discussion on CAR-T in Myeloma - James R. Berenson, MD; Sham Mailankody, MBBS; Deepu Madduri, MD; Adam D. Cohen, MD

31/12/2019 Duração: 07min

New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies

Ouvir
CAR-Ts: What are the Next-Gen Products and Strategies? - Adam D. Cohen, MD

31/12/2019 Duração: 21min

New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies

Ouvir
Dealing with Adverse Events and Toxicities in CAR-T cell Therapy - Deepu Madduri, MD

31/12/2019 Duração: 22min

New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies

Ouvir
Responses to CAR-T Therapy in Multiple Myeloma - Sham Mailankody, MBBS

31/12/2019 Duração: 17min

New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies

Ouvir
The Role of BCMA in Predicting Outcomes and Monitoring MM and CLL - James R. Berenson, MD

31/12/2019 Duração: 20min

New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies

Ouvir
Mantle Cell Lymphoma: New and Emerging Agents - Michael E. Williams, MD

31/12/2019 Duração: 19min

Mantle Cell Lymphoma: New and Emerging Agents

Ouvir
Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic and Targeted Approaches - John P. Leonard, MD

31/12/2019 Duração: 20min

Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic and Targeted Approaches

Ouvir
Who Should Receive CAR-T Cell Therapy for Lymphoma - Craig S. Sauter, MD

31/12/2019 Duração: 21min

Treatment for Marginal Zone Lymphoma: Should it be Different from FL?

Ouvir
Panel Discussion: Marginal Zone Lymphoma - Thomas M. Habermann, MD and John P. Leonard, MD

31/12/2019 Duração: 01min

Treatment for Marginal Zone Lymphoma: Should it be Different from FL?

Ouvir
Treatment for Marginal Zone Lymphoma: Should it be Different from Follicular Lymphoma? - Thomas M. Habermann, MD

31/12/2019 Duração: 19min

Treatment for Marginal Zone Lymphoma: Should it be Different from FL?

Ouvir
Who Should Receive CAR-T Cell Therapy for Lymphoma - Craig S. Sauter, MD

31/12/2019 Duração: 21min

Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma

Ouvir
Panel Discussion: 'Great' Debates in Follicular Lymphoma - John P. Leonard, MD; Carla Casulo, MD; Bruce D. Cheson, MD; Richard I. Fisher, MD; Thomas M. Habermann, MD; Peter Martin, MD

31/12/2019 Duração: 08min

Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma

Ouvir
Debate: Chemotherapy no Longer Has a Major Role in the Treatment of Follicular Lymphoma - Bruce D. Cheson, MD and Richard I. Fisher, MD

31/12/2019 Duração: 22min

Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma

Ouvir
Debate: Watch and Wait in Follicular Lymphoma: Should We Treat Immediately? - Peter Martin, MD and Carla Casulo, MD

31/12/2019 Duração: 33min

Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma

Ouvir
Panel Discussion on 'Great' Debates in Follicular Lymphoma - John P. Leonard, MD; Carla Casulo, MD; Bruce D. Cheson, MD; Richard I. Fisher, MD; Thomas M. Habermann, MD; Peter Martin, MD

31/12/2019 Duração: 08min

Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors

Ouvir
Debate: Does Chemotherapy Still Have a Major Role to Play in the Treatment of FL? - Bruce D. Cheson, MD and Richard I. Fisher, MD

31/12/2019 Duração: 22min

Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors

Ouvir
Debate: Watch and Wait in Follicular Lymphoma or Should We Treat Immediately? - Peter Martin, MD and Carla Casulo, MD

31/12/2019 Duração: 33min

Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors

Ouvir
Epigenetic Therapy for Lymphoma: From the Laboratory to the Clinic - Ari M. Melnick, MD

31/12/2019 Duração: 22min

Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors

Ouvir
Panel Discussion: Hairy Cell Leukemia - Jacqueline C. Barrientos, MD, MS and Jae Park, MD

31/12/2019 Duração: 16min

Hairy Cell Leukemia: New and Emerging Agents

Ouvir

página 3 de 20

Imedex E-learning (audio)

Sinopse

Episódios

Chemotherapy vs Novel Agents in Young CLL Patients: Is There Still a Role for Chemotherapy? - Neil E. Kay, MD

Panel Discussion on CAR-T in Myeloma - James R. Berenson, MD; Sham Mailankody, MBBS; Deepu Madduri, MD; Adam D. Cohen, MD

CAR-Ts: What are the Next-Gen Products and Strategies? - Adam D. Cohen, MD

Dealing with Adverse Events and Toxicities in CAR-T cell Therapy - Deepu Madduri, MD

Responses to CAR-T Therapy in Multiple Myeloma - Sham Mailankody, MBBS

The Role of BCMA in Predicting Outcomes and Monitoring MM and CLL - James R. Berenson, MD

Mantle Cell Lymphoma: New and Emerging Agents - Michael E. Williams, MD

Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic and Targeted Approaches - John P. Leonard, MD

Who Should Receive CAR-T Cell Therapy for Lymphoma - Craig S. Sauter, MD

Panel Discussion: Marginal Zone Lymphoma - Thomas M. Habermann, MD and John P. Leonard, MD

Treatment for Marginal Zone Lymphoma: Should it be Different from Follicular Lymphoma? - Thomas M. Habermann, MD

Who Should Receive CAR-T Cell Therapy for Lymphoma - Craig S. Sauter, MD

Panel Discussion: 'Great' Debates in Follicular Lymphoma - John P. Leonard, MD; Carla Casulo, MD; Bruce D. Cheson, MD; Richard I. Fisher, MD; Thomas M. Habermann, MD; Peter Martin, MD

Debate: Chemotherapy no Longer Has a Major Role in the Treatment of Follicular Lymphoma - Bruce D. Cheson, MD and Richard I. Fisher, MD

Debate: Watch and Wait in Follicular Lymphoma: Should We Treat Immediately? - Peter Martin, MD and Carla Casulo, MD

Panel Discussion on 'Great' Debates in Follicular Lymphoma - John P. Leonard, MD; Carla Casulo, MD; Bruce D. Cheson, MD; Richard I. Fisher, MD; Thomas M. Habermann, MD; Peter Martin, MD

Debate: Does Chemotherapy Still Have a Major Role to Play in the Treatment of FL? - Bruce D. Cheson, MD and Richard I. Fisher, MD

Debate: Watch and Wait in Follicular Lymphoma or Should We Treat Immediately? - Peter Martin, MD and Carla Casulo, MD

Epigenetic Therapy for Lymphoma: From the Laboratory to the Clinic - Ari M. Melnick, MD

Panel Discussion: Hairy Cell Leukemia - Jacqueline C. Barrientos, MD, MS and Jae Park, MD

Experimente 30 dias grátis

Precisando de ajuda?

Instale o aplicativo:

Imedex E-learning (audio)

Informações:

Sinopse

Episódios

Chemotherapy vs Novel Agents in Young CLL Patients: Is There Still a Role for Chemotherapy? - Neil E. Kay, MD

Panel Discussion on CAR-T in Myeloma - James R. Berenson, MD; Sham Mailankody, MBBS; Deepu Madduri, MD; Adam D. Cohen, MD

CAR-Ts: What are the Next-Gen Products and Strategies? - Adam D. Cohen, MD

Dealing with Adverse Events and Toxicities in CAR-T cell Therapy - Deepu Madduri, MD

Responses to CAR-T Therapy in Multiple Myeloma - Sham Mailankody, MBBS

The Role of BCMA in Predicting Outcomes and Monitoring MM and CLL - James R. Berenson, MD

Mantle Cell Lymphoma: New and Emerging Agents - Michael E. Williams, MD

Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic and Targeted Approaches - John P. Leonard, MD

Who Should Receive CAR-T Cell Therapy for Lymphoma - Craig S. Sauter, MD

Panel Discussion: Marginal Zone Lymphoma - Thomas M. Habermann, MD and John P. Leonard, MD

Treatment for Marginal Zone Lymphoma: Should it be Different from Follicular Lymphoma? - Thomas M. Habermann, MD

Who Should Receive CAR-T Cell Therapy for Lymphoma - Craig S. Sauter, MD

Panel Discussion: 'Great' Debates in Follicular Lymphoma - John P. Leonard, MD; Carla Casulo, MD; Bruce D. Cheson, MD; Richard I. Fisher, MD; Thomas M. Habermann, MD; Peter Martin, MD

Debate: Chemotherapy no Longer Has a Major Role in the Treatment of Follicular Lymphoma - Bruce D. Cheson, MD and Richard I. Fisher, MD

Debate: Watch and Wait in Follicular Lymphoma: Should We Treat Immediately? - Peter Martin, MD and Carla Casulo, MD

Panel Discussion on 'Great' Debates in Follicular Lymphoma - John P. Leonard, MD; Carla Casulo, MD; Bruce D. Cheson, MD; Richard I. Fisher, MD; Thomas M. Habermann, MD; Peter Martin, MD

Debate: Does Chemotherapy Still Have a Major Role to Play in the Treatment of FL? - Bruce D. Cheson, MD and Richard I. Fisher, MD

Debate: Watch and Wait in Follicular Lymphoma or Should We Treat Immediately? - Peter Martin, MD and Carla Casulo, MD

Epigenetic Therapy for Lymphoma: From the Laboratory to the Clinic - Ari M. Melnick, MD

Panel Discussion: Hairy Cell Leukemia - Jacqueline C. Barrientos, MD, MS and Jae Park, MD

Títulos relacionados

Experimente 30 dias grátis

Precisando de ajuda?

Instale o aplicativo: